A Prospective Randomized Comparison of HDAC vs AD in the Induction Chemothrapy for AML.
Status:
Enrolling by invitation
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
This trial is a single-center, non-blind, two-arm randomized prospective controlled trial to
compare the effectiveness of two induction chemotherapy regimens (high-dose cytarabine plus
daunorubicin [HDAC] vs. cytarabine plus high-dose daunorubicin [AD]) in acute myeloid
leukemia (AML). The primary hypothesis of the study is that AD is superior to HDAC in terms
of event-free survival (EFS, time from registration to induction failure, relapse, or death).